BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

First international progressive supranuclear palsy research and treatment centre opens in Korea

December 9, 2024 | News

To address the pressing global challenges posed by conditions in an ageing society



Seoul National University Bundang Hospital (SNUBH), CurePSP, Inc. and GemVax & KAEL Co., have announced the establishment of Korea's first International Progressive Supranuclear Palsy (PSP) Research and Treatment Centre.

The three organisations have signed a tripartite Memorandum of Understanding (MoU) to create a comprehensive centre, dedicated to advancing research and treatment for PSP and other neurological conditions as well as various conditions related addictions. This initiative aims to address the pressing global challenges posed by such conditions in an ageing society through advancements in research, education, medical care, treatment and commercialisation thereof.

The International PSP Research and Treatment Centre will integrate the infrastructure and expertise of the three parties to execute a comprehensive array of functions, including education, research, and treatment, as well as the potential commercialisation of therapies for PSP and other neurological conditions. Additionally, the Centre will address coexisting or related conditions, including behavioural and neurological disorders linked to addiction, with a specific focus on substance abuse.

SNUBH will support the stable operation of the center and lead advancements in medical care, education, and research. CurePSP, a US-based nonprofit charitable organisation, drawing upon its 30 years of global experience, will act as an advisor, connector, and subject matter expert in all aspects of the Centre's development and will provide guidance on best practices for PSP care, education, and research initiatives while leveraging its extensive global network to establish the international connections necessary for the Centre's success. GemVax will provide funding and oversee the process necessary for the establishment of the Centre while spearheading the research, development, and commercialisation of PSP therapeutics.